Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (GB:0IIM)
LSE:0IIM
Esperion (0IIM) Share Price & Analysis
0 Followers
0IIM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.71 - $3.37
Previous Close$2.08
Volume8.92K
Average Volume (3M)21.33K
Market Cap
$356.17M
Enterprise Value$540.09M
Total Cash (Recent Filing)$82.25M
Total Debt (Recent Filing)$266.17M
Price to Earnings (P/E)N/A
Beta2.83
Next Earnings
May 07, 2024EPS Estimate
$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding185,052,705
10 Day Avg. Volume386
30 Day Avg. Volume21,331
Standard Deviation0.15
R-Squared0.04
Alpha-0.00639
Financial Highlights & Ratios
Price to Book (P/B)-0.78
Price to Sales (P/S)52.55
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.64
Enterprise Value/Gross Profit4.64
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$7.41Price Target Upside257.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Esperion News
Bulls Say, Bears Say
Bulls Say
Commercial StrategyManagement's detailed commercial expansion plan aims to capitalize on the expanded drug label, driving broader use and potentially increasing the value of the company's shares.
Label ExpansionThe FDA's approval of the CLEAR label expansion represents a seminal moment for the company, potentially tripling the number of patients eligible for the drug and enhancing its market potential.
Market OpportunityWith the label expansion, the drug's total addressable market in the U.S. has increased significantly, offering a substantial growth opportunity for the company's sales.
Bears Say
Financial HeadwindsPotential balance sheet headwinds still looming.
Market Penetration DifficultyCapturing meaningful share may not be straightforward in the primary prevention market due to underutilization of generic and more effective statins.
Marketing ChallengesMaximizing the impact of this positive label may take some significant marketing muscle at a time when Esperion is cash-strapped.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
7.63% Other Institutional Investors
92.37% Public Companies and
Individual Investors
0IIM FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest share price was $0.71 and its highest was $3.37 in the past 12 months.
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is May 07, 2024 which is in 13 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Feb 27, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.018.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is $0.05.
How many shares outstanding does Esperion have?
Currently, no data Available
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went up 10.925%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Platinum Investment Management. It holds Esperion’s shares valued at 8M.
---
Esperion Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.41 (257.11% Upside)
$7.41 (257.11% Upside)
Blogger Sentiment
Bullish
GB:0IIM Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.00%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
0IIM Company Deck
---
0IIM Earnings Call
Q4 2024
0:00 / 0:00
---
0IIM Stock 12 Months Forecast
Average Price Target
$7.41
▲(257.11% Upside)
Technical Analysis
Best Analysts Covering 0IIM
1 Year
1 Year Success Rate
9/26 ratings generated profit
1 Year Average Return
+27.37%
reiterated a buy rating last month
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 34.62% of your transactions generating a profit, with an average return of +27.37% per trade.
---